| Literature DB >> 35582398 |
Peijie Zhu1,2, Weijia Chen2,3, Qiqin Wang2,4, Huihui Wu2, Meng Ruan2, Hongwu Wang1, Zhengjin Jiang2,4.
Abstract
In this research, a new phospholipid based monolith was fabricated by in situ co-polymerization of 1-dodecanoyl-2-(11-methacrylamidoundecanoyl)-sn-glycero-3-phosphoethanolamine and ethylene dimethacrylate to mimick bio-membrane environment. Excellent physicochemical properties of this novel monolith that were achieved included column efficiency, stability, and permeability. Moreover, the biomimetic monolith showed outstanding separation capability for a series of intact proteins and small molecules. In particular, it exhibited good potential as an alternative to the commercial immobilized artificial membrane (IAM) column (IAM.PC.DD2) for studying drug-membrane interactions. This study not only enriched the types of IAM stationary phases, but also provided a simple model for the prediction of phosphatidylethanolamine related properties of drug candidates.Entities:
Keywords: Biomimetic monolith; Drug-membrane interaction; IAM; Phosphatidylethanolamine
Year: 2021 PMID: 35582398 PMCID: PMC9091901 DOI: 10.1016/j.jpha.2021.09.002
Source DB: PubMed Journal: J Pharm Anal ISSN: 2214-0883
Fig. 1Preparation of the poly(1-dodecanoyl-2-(11-methacrylamidoundecanoyl)-sn-glycero-3-phosphoethanolamine (MDSPE)-co-ethylene dimethacrylate (EDMA)) monolith by in-situ copolymerization method. AIBN: 2,2′-azobisisobutyronitrile.
Composition of the polymerization mixtures used for the preparation of the poly(1-dodecanoyl-2-(11-methacrylamidoundecanoyl)-sn-glycero-3-phosphoethanolamine (MDSPE)-co-ethylene dimethacrylate (EDMA)) monolith.
| Column | Monomers (%, | Porogens (%, | Monomers:porogens (%, | Back-pressure (MPa) | Column efficiency (theoretical plates/m) | |||
|---|---|---|---|---|---|---|---|---|
| MDSPE | EDMA | MeOH | Tetrahydrofuran | Monomers | Porogens | |||
| C1 | 59 | 41 | 51 | 49 | 33 | 67 | 7.2 | 20000 |
| C2 | 59 | 41 | 51 | 49 | 28 | 72 | 5.2 | 32000 |
| C3 | 59 | 41 | 51 | 49 | 23 | 77 | 1.5 | 11000 |
| C4 | 64 | 36 | 51 | 49 | 28 | 72 | 5.4 | 24000 |
| C5 | 54 | 46 | 51 | 49 | 28 | 72 | 4.0 | 26000 |
| C6 | 59 | 41 | 46 | 54 | 28 | 72 | 10.2 | 12000 |
| C8 | 59 | 41 | 61 | 39 | 28 | 72 | 0.3 | 28000 |
| C9 | 59 | 41 | 66 | 34 | 28 | 72 | 0.1 | 8000 |
Conditions: column dimensions: 120 mm × 100 μm i.d.; mobile phase: H2O:acetonitrile (ACN) (60:40, V/V); UV detection wavelength: 214 nm; flow rate: 400 nL/min; injection volume: 20 nL; sample: anisole.
Fig. 2Scanning electron microscopy images of column C7.
Permeability of the poly(MDSPE-co-EDMA) monolithic column [33].
| Mobile phase | Relative polarity | Viscosity (×103, Pa·s) | Permeability ( |
|---|---|---|---|
| ACN | 0.460 | 0.369 | 4.91 |
| MeOH | 0.762 | 0.544 | 4.35 |
| H2O | 1.000 | 0.890 | 3.25 |
Reproducibility of retention time on the poly(MDSPE-co-EDMA) monolith.
| Reproducibility | RSDToluene(%) | RSDThiourea(%) |
|---|---|---|
| Run-to-run ( | 1.3 | 1.7 |
| Day-to-day ( | 1.5 | 2.5 |
| Column-to-column ( | 0.6 | 1.9 |
| Batch-to-batch ( | 3.0 | 5.3 |
Experimental conditions: column dimensions: 150 mm × 100 μm i.d.; mobile phase: H2O:ACN (60:40, V/V); UV detection wavelength: 214 nm; flow rate: 400 nL/min; injection volume: 20 nL; sample: toluene, thiourea. RSD: relative standard deviations.
Fig. 3Separation of proteins on the poly(MDSPE-co-EDMA) monolith. Experimental conditions: column dimensions: 240 mm × 100 μm i.d.; UV detection wavelength: 280 nm; mobile phase: 0.1% trifluoroacetic acid (TFA) in H2O (A), 0.1% TFA in acetonitrile (ACN) (B); gradient: 0 min, 25% B; 20 min, 90% B; 20.5 min, 25% B; 25 min, 25% B; flow rate: 1200 nL/min. Cyt c: cytochrome c.
Fig. 4Separation of drugs on the poly(MDSPE-co-EDMA) monolith. Experimental conditions: column dimension: 170 mm × 100 μm i.d.; mobile phase: H2O containing 50 mM ammonium acetate (pH 7.4) (A), ACN (B); gradient: 0 min, 10% B; 15.0 min, 100% B; 18.0 min, 100% B; 18.5 min, 10% B; 26.0 min, 10% B; detection wavelength: 214 nm; flow rate: 600 nL/min; injection volume: 20 nL; samples: (1) 6-hydroxydopamine; (2) sulfanilamide; (3) hydrochlorothiazide; (4) lidocaine; (5) ketoconazde; (6) tioconazole; (7) amodiaquine; and (8) amiodarone.
Selected drugs and their log P, chromatographic hydrophobicity index (CHI) immobilized artificial membrane (IAM)7.4 (MDSPE), CHI IAM7.4 (MDSPC), CHI IAM7.4 (PC.DD2) values.
| Compounds | log | CHI IAM7.4 (MDSPE)b | CHI IAM7.4(MDSPC)c | CHI IAM7.4(PC.DD2)d |
|---|---|---|---|---|
| Amiodarone | 7.20 | 70.50 | 51.17 | 73.81 |
| Amitriptyline | 4.92 | 53.64 | 24.80 | 47.19 |
| Carbamazepine | 2.77 | 20.59 | 19.63 | 22.18 |
| Chlorpromazine | 5.41 | 61.26 | 31.79 | 56.04 |
| Clozapine | 3.23 | 47.78 | 32.14 | 45.90 |
| Diclofenac | 4.51 | 23.01 | 27.51 | 34.48 |
| Diltiazem | 2.80 | 35.79 | 18.39 | 31.69 |
| Fluoxetine | 4.05 | 55.20 | 28.05 | 48.76 |
| Hydrocortisone | 1.61 | 17.96 | 18.31 | 21.88 |
| Lidocaine | 2.44 | 24.91 | 15.12 | 29.51 |
| Metolazone | 2.50 | 28.09 | 21.08 | 18.16 |
| Nitrendipine | 2.88 | 36.16 | 36.76 | 38.80 |
| Oxprenolol | 2.10 | 38.03 | −11.44 | 29.17 |
| Phenoxybenzamine | 4.70 | 55.57 | 45.35 | 52.09 |
| Pindolol | 1.75 | 40.45 | −7.79 | 31.62 |
| Promethazine | 4.81 | 22.62 | 28.22 | 22.15 |
| Terbutaline | 0.90 | 16.96 | −26.30 | 18.19 |
| Theophylline | −0.02 | −19.38 | −29.78 | −11.88 |
| Thioridazine | 5.90 | 65.23 | 33.56 | 58.03 |
| Tioconazole | 4.40 | 46.36 | 42.81 | 49.75 |
| Verapamil | 5.23 | 39.82 | 22.80 | 37.49 |
| 4-hydroxycoumarin | 1.01 | −20.68 | −27.30 | −1.98 |
| 6-hydroxydopamine | / | −20.97 | −33.41 | −34.97 |
| Acetazolamide | −0.26 | −16.89 | −19.48 | −7.76 |
| Amodiaquine | 3.70 | 59.11 | 32.53 | 48.82 |
| Atropine | 1.83 | 20.18 | −27.23 | 25.06 |
| Auramine O | / | 54.66 | 40.82 | 42.94 |
| Caffeine | −0.07 | −18.59 | −29.24 | −13.20 |
| Cimetidine | 0.40 | −11.28 | −26.56 | 9.38 |
| Clofibrate | 3.30 | 40.13 | 38.30 | 40.39 |
| Dibucaine | 4.40 | 48.22 | 22.30 | 53.73 |
| 2,6-pyridinedicarboxylic acid | −0.44 | −21.22 | −32.61 | −24.77 |
| Disopyramide | 2.58 | 20.62 | −26.91 | 24.72 |
| Hydroxyzine | 3.43 | 42.69 | 26.41 | 39.85 |
| Indapamide | 2.52 | 30.37 | 30.83 | 26.75 |
| Isoniazid | −0.70 | −20.39 | −31.43 | −20.48 |
| Menadione | 2.20 | 32.32 | 31.74 | 27.33 |
| Methotrexate | −1.85 | −21.36 | −31.37 | −10.27 |
| Ofloxacin | −0.39 | −20.95 | −32.71 | −24.00 |
| Procaine | 2.14 | 24.00 | 18.23 | 10.10 |
| Quinine | 3.44 | 47.65 | 12.35 | 41.35 |
| Rifampin | 2.70 | 24.57 | 22.37 | 29.24 |
| Sotalol | −0.40 | 14.45 | −28.95 | 11.48 |
| Sulfanilamide | −0.62 | −13.37 | −18.11 | −17.94 |
| Tert-butylhydroquinone | 2.91 | 32.01 | 35.12 | 34.89 |
| Trimipramine | 4.20 | 51.77 | 25.90 | 47.54 |
| Amlodipine maleate | / | 55.45 | 24.71 | 51.73 |
| Ketoconazole | 4.35 | 32.97 | 28.85 | 36.39 |
| Citalopram hydrobromide | / | 44.10 | 13.19 | 40.04 |
| Tobramycin | −5.80 | −20.97 | −33.73 | −23.93 |
| Amikacin | −3.20 | −21.46 | −33.67 | −24.06 |
| Imipramine | 4.80 | 51.90 | 21.66 | 46.70 |
| Carbamazepine | 2.77 | 20.52 | 20.35 | 25.31 |
| Mianserin | 3.83 | 47.77 | 34.05 | 47.39 |
| Desipramine·HCl | / | 56.08 | 22.73 | 50.79 |
| Clomipramine | 5.19 | 57.16 | 29.34 | 53.57 |
| Chlorphentermine | 2.60 | 13.18 | 7.07 | 41.24 |
| Nortriptyline | 3.90 | 55.18 | 23.23 | 52.90 |
| Imipramine | 4.80 | 56.08 | 19.84 | 46.70 |
| Desipramine | 4.90 | 55.30 | 23.68 | 48.26 |
| Clomipramine | 5.19 | 57.47 | 29.04 | 51.30 |
| Oxazepam | 2.24 | 27.53 | 28.46 | 33.60 |
| Pentobarbital sodium | / | 19.80 | 21.33 | 24.38 |
| Hexobarbital | 1.98 | 20.20 | 19.42 | 20.20 |
| Domperidone | 3.90 | 42.33 | 26.69 | 41.24 |
| Clonidine | 1.59 | 31.20 | −8.27 | 29.01 |
| Prochlorperazine | 4.88 | 54.86 | 31.53 | 57.05 |
| Theobromine | −0.78 | −15.12 | −33.33 | −12.84 |
| Benzene | / | 28.21 | 25.92 | 24.54 |
| Toluene | 2.73 | 34.56 | 32.94 | 33.26 |
Experimental conditions: a log P values were from DrugBank database; b the conditions for poly(MDSPE-co-EDMA) monolith, see Fig. 4; c poly(MDSPC-co-EDMA) column dimension (130 mm × 100 μm); mobile phase: 50 mM ammonium acetate (pH 7.4) buffer (A), ACN (B); gradient: 0 min, 10% B; 15.0 min, 100% B; 18.0 min, 100% B; 18.5 min, 10% B; 26.0 min, 10% B; detection wavelength: 214 nm or 254 nm; flow rate: 600 nL/min; injection volume: 20 nL; d Regis IAM.PC.DD2 column dimension (100 mm × 4.6 mm i.d., 10 μm); mobile phase: 50 mM ammonium acetate (pH 7.4) buffer (A); ACN (B); gradient: 0 min, 0% B; 6.0 min, 100% B; 6.5 min, 100% B; 7.0 min, 0% B; 9.0 min, 0% B; detection wavelength: 214 nm; flow rate: 1.0 mL/min; injection volume: 20 μL. MDSPC: 1-dodecanoyl-2-(11-methacrylamidoundecanoyl)-sn-glycero-3-phosphocholine; PC: phosphatidylcholine.
Fig. 5(A) Spearman's correlations between chromatographic hydrophobicity index (CHI) immobilized artificial membrane (IAM)7.4(PC.DD2) values and CHI IAM7.4(MDSPE) values. (B) Spearman's correlations between CHI IAM7.4 (MDSPE) values and CHI IAM7.4 (MDSPC) values. MDSPC: 1-dodecanoyl-2-(11-methacrylamidoundecanoyl)-sn-glycero-3-phosphocholine.